



Letter to the Editor

Cancerous Patient with COVID-19: Note on Data from the first 3-Month Period of Disease

Beuy Joob¹ Viroj Wiwanitkit²¹Sanitation 1 Medical Academic Center, Bangkok, Thailand²Department of Community Medicine, Dr. D.Y. Patil University, Pune, Maharashtra, India

South Asian J Cancer:2020;9:120

Coronavirus disease 2019 (COVID-19) is an important pandemic. From its origin in Republic of China,¹ this disease already affects more than 200 countries around the world. The infection can occur in any sex and age group. Malignancy is a possible comorbidity of COVID-19. There are few reported cases of COVID-19 in clinical oncology.² Here, the authors would like to share public data reported by local Center for Disease Control and Prevention of the second country where this disease occurred since January 2020.³ During the 3-month period (January 2020–March 2020), there were 1,651 cases of COVID-19 with 10 deaths. There is a patient with underlying cancer, giving the incidence rate equal to 0.06%. This indexed case is a 48-year-old male patient who works as a singer in a local food shop. He is a known case of colon cancer who had just received surgery and chemotherapy for a few months (the complete chemotherapy was 3 months before). The patient died from respiratory failure on day 5 of hospitalization for antiviral therapy and isolated respiratory care. This is the first data of cancerous patient with COVID-19 from Indochina, an area with a heavy outbreak of COVID-19. According to the reports from Republic of China, malignancy might be associated with poor outcome in COVID-19.⁴ Nevertheless, no conclusion should be presently drawn in out setting since it is only one event. It might only imply possibility for poor outcome in case with underlying malignancy.

Address for correspondence Professor Viroj Wiwanitkit, Department of Community Medicine, Dr D.Y. Patil University, Pune 400706, Maharashtra, India (e-mail: vviroj@yahoo.com).

Declaration of Patient Consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published, and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial Support and Sponsorship

None.

Conflict of Interest

There are no conflicts of interest.

References

- 1 Hsia W. Emerging new coronavirus infection in Wuhan, China: situation in early 2020. *Case Study Case Rep* 2020;101:8–9
- 2 Yang L, Xu HY, Wang Y. Diagnostic and therapeutic strategies of lung cancer patients during the outbreak of 2019 novel coronavirus disease (COVID-19) [in Chinese]. *Zhonghua Zhong Liu Za Zhi* 2020;42(4):292–295
- 3 Yasri S, Wiwanitkit V. Editorial: Wuhan coronavirus outbreak and imported case. *Adv Trop Med Public Health Int* 2020; 10:1–2
- 4 Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. *Clin Infect Dis* 2020;71(15):769–777

DOI <https://doi.org/10.1055/s-0040-1721214>
ISSN 2278-330X.

© 2020. MedIntel Services Pvt Ltd.

This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (<https://creativecommons.org/licenses/by-nc-nd/4.0/>)

Thieme Medical and Scientific Publishers Pvt. Ltd., A-12, 2nd Floor, Sector 2, Noida-201301 UP, India